Packer, M. et al. (2017) Effect of ularitide on cardiovascular mortality in acute heart failure. New England Journal of Medicine, 376(20), pp. 1956-1964. (doi: 10.1056/NEJMoa1601895) (PMID:28402745)
|
Text
140192.pdf - Published Version 388kB |
Abstract
Background: In patients with acute heart failure, early intervention with an intravenous vasodilator has been proposed as a therapeutic goal to reduce cardiac-wall stress and, potentially, myocardial injury, thereby favorably affecting patients' long-term prognosis. Methods: In this double-blind trial, we randomly assigned 2157 patients with acute heart failure to receive a continuous intravenous infusion of either ularitide at a dose of 15 ng per kilogram of body weight per minute or matching placebo for 48 hours, in addition to accepted therapy. Treatment was initiated a median of 6 hours after the initial clinical evaluation. The coprimary outcomes were death from cardiovascular causes during a median follow-up of 15 months and a hierarchical composite end point that evaluated the initial 48-hour clinical course. Results: Death from cardiovascular causes occurred in 236 patients in the ularitide group and 225 patients in the placebo group (21.7% vs. 21.0%; hazard ratio, 1.03; 96% confidence interval, 0.85 to 1.25; P=0.75). In the intention-to-treat analysis, there was no significant between-group difference with respect to the hierarchical composite outcome. The ularitide group had greater reductions in systolic blood pressure and in levels of N-terminal pro-brain natriuretic peptide than the placebo group. However, changes in cardiac troponin T levels during the infusion did not differ between the two groups in the 55% of patients with paired data. Conclusions: In patients with acute heart failure, ularitide exerted favorable physiological effects (without affecting cardiac troponin levels), but short-term treatment did not affect a clinical composite end point or reduce long-term cardiovascular mortality. (Funded by Cardiorentis; TRUE-AHF ClinicalTrials.gov number, NCT01661634.).
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Petrie, Professor Mark and McMurray, Professor John |
Authors: | Packer, M., O'Connor, C., McMurray, J. J.V., Wittes, J., Abraham, W. T., Anker, S. D., Dickstein, K., Filippatos, G., Holcomb, R., Krum, H., Maggioni, A. P., Mebazaa, A., Peacock, W. F., Petrie, M. C., Ponikowski, P., Ruschitzka, F., van Veldhuisen, D. J., Kowarski, L. S., Schactman, M., and Holzmeister, J. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
Journal Name: | New England Journal of Medicine |
Publisher: | Massachusetts Medical Society |
ISSN: | 0028-4793 |
ISSN (Online): | 1533-4406 |
Published Online: | 12 April 2017 |
Copyright Holders: | Copyright © 2017 Massachusetts Medical Society |
First Published: | First published in New England Journal of Medicine 376(20): 1956-1964 |
Publisher Policy: | Reproduced in accordance with the publisher copyright policy |
University Staff: Request a correction | Enlighten Editors: Update this record